Promises and challenges of a decentralized CAR T-cell manufacturing model

Promises and challenges of a decentralized CAR T-cell manufacturing model

Autologous chimeric antigen receptor-modified T-cell (CAR T) products have demonstrated un-precedent efficacy in treating many relapsed/refractory B-cell and plasma cell malignancies, leading to multiple commercial products now in routine clinical use. These positive responses to CAR T therapy have...

Full description

Bibliographic Details
Main Authors: Manan Shah, Ashley Krull, Lynn Odonnell, Marcos J. de Lima, Evandro Bezerra
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Transplantation
Subjects:
decentralized
CAR T
leukapheresis
chimeric
lentivirus
Online Access:https://www.frontiersin.org/articles/10.3389/frtra.2023.1238535/full

Internet

https://www.frontiersin.org/articles/10.3389/frtra.2023.1238535/full

Similar Items